Summary: In a phase Ib/IIa proof-of-concept trial of 60 patients with MASLD and type 2 diabetes, five weekly subcutaneous doses of the GLP-1/FGF21 dual agonist HEC88473 produced dose-proportional liver fat reduction, with the largest relative MRI-PDFF change reaching -47.21% (p=0.0143) in the 30.6 mg cohort versus -15.05% with placebo. Glycaemic and lipid measures also improved, and gastrointestinal adverse events were common (48.3%). These early findings are exploratory, not confirmatory.
PICO Summary
| Element | Detail |
|---|---|
| Population | 60 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM); randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib/IIa trial conducted in China. |
| Intervention | HEC88473 (GLP-1/FGF21 dual agonist) by weekly subcutaneous injection for 5 weeks, across five ascending dose cohorts (5.1, 15.3, 30.6, 45.9, or 68.0 mg); patients randomized 10:2 to active drug or placebo within each cohort. |
| Comparison | Matching placebo by weekly subcutaneous injection (pooled placebo arm). |
| Outcome | Liver fat (MRI-PDFF) fell dose-proportionally; the largest relative mean change was -47.21% (p=0.0143) in the 30.6 mg cohort versus -15.05% in placebo, with more >30% relative reductions among patients with baseline PDFF >8%. The largest mean HbA1c change was -1.10% (68.0 mg cohort) versus -0.31% in placebo; fasting and postprandial glucose and lipid profiles also improved. Gastrointestinal disorders were the most frequent adverse events (n=29, 48.3%); most adverse events were mild to moderate. Confidence intervals, absolute risk reduction, and number needed to treat were not reported for this small early-phase study. |
HEC88473 in MASLD and T2DM
Phase Ib/IIa RCT · MASLD + T2DM · 5 weeks
In this early proof-of-concept trial, weekly HEC88473 cut liver fat dose-proportionally, with the 30.6 mg cohort reaching a -47.21% relative MRI-PDFF change versus -15.05% on placebo. Findings are exploratory and need larger, longer, independent trials.
Expert Commentary
This is an early-phase, proof-of-concept study rather than a demonstration of established efficacy, and the verdict should be read in that light. The signal is biologically plausible and internally consistent: liver fat measured by MRI-PDFF was reduced in a dose-proportional manner, and glycaemic and lipid measures moved in the expected direction, which is encouraging for a GLP-1/FGF21 dual agonist. Several important caveats temper enthusiasm. The trial enrolled only 60 patients with an uneven 10:2 allocation, treatment lasted just 5 weeks, and the endpoints were imaging and biochemical surrogates rather than histology or clinical outcomes. The headline -47.21% figure reflects the best-performing single cohort, so it should not be generalised across doses. The most weighed limitation is sponsorship: several authors are employees of the manufacturer, which warrants caution given the implausibly large effect relative to the brief exposure. Gastrointestinal events affected nearly half of participants, consistent with the incretin class. Can I use this with my patients? Not yet. HEC88473 is investigational and unavailable outside trials, and no patient type can be offered it on the basis of these data. Larger, longer, independently funded phase II/III trials with histological and hard clinical endpoints are needed before any clinical role can be defined.
References
Xiang L, Wang G, Zhuang Y, et al. Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(6):967-978. doi:10.1016/j.jhep.2024.12.006